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Reply to FOLFIRI plus cetuximab
versus FOLFIRI plus
bevacizumab as ﬁrst-line
treatment for patients with
metastatic colorectal cancer–
subgroup analysis of patients
with KRAS-mutated tumours in
the randomised German AIO
study KRK-0306
We read with great interest the article of Stintzing et al.
published in Annals of Oncology on July 2012 [1] and would
make a few remarks.
The results of this unplanned retrospective analysis, carried
out on 96 KRAS-mutated colorectal cancer patients, did not
show any substantial difference in terms of response rate,
progression-free and overall survival between anti-epidermal
growth factor receptor- and anti-vascular endothelial growth
factor-based treatments. These results may be just related to
operative bias: for example, the similar response rate observed
in the cetuximab and bevacizumab arms is explainable by the
lack of independent radiological review and the limitation of
standard radiological assessment for anti-angiogenic
treatments, which may delay disease progression mainly
through disease stabilization: in fact, biological response is
often characterized by a reduction of lesions’ density, without a
substantial RECIST response [2].
Overall survival seemed to favour cetuximab over
bevacizumab (22.7 versus 18.7 months), although this
difference was not statistically signiﬁcant (HR = 0.86, 95% CI,
0.55–1.35; P = 0.55). Since cetuximab arm was affected by a
higher and earlier dropout rate, it is possible that lower median
treatment duration in the cetuximab arm may have led to
earlier initiation of effective bevacizumab-based second-line
treatment. In fact, half of the patients treated with FOLFIRI
plus cetuximab received subsequent bevacizumab-based
regimens. Not surprisingly, a combination of bevacizumab and
oxaliplatin-based regimens was shown to prolong overall
survival in the second-line setting [3].
Even though the addition of cetuximab to FOLFIRI regimen
seems to be at least not detrimental for progression-free
survival in KRAS-mutated patients, [4] the apparent lack of
beneﬁt from the addition of bevacizumab could also derive
from confounding factors and imbalance between prognostic
factors rather than KRAS mutation itself. For example, the rate
of patients undergoing surgery was twice as high in the
cetuximab arm: although this is clearly not attributable to
treatment (given the identical response rate in both the arms),
a multimodality strategy may have improved progression-free
and overall survival in patients treated with the cetuximab-
based combination.
The authors stated that KRAS G13D mutations, found in
20% of cases, may be associated with poorer prognosis
independently of the treatment arm. However, in the recently
published pooled analysis of CRYSTAL and OPUS trials, KRAS
G13D-mutated patients receiving ﬁrst-line chemotherapy alone
failed to show a statistically signiﬁcant difference in terms of
progression-free survival and overall survival, when compared
with other KRAS-mutated subtypes [5].
We believe that the study of Stintzing et al. is particularly
valuable because it stimulates the investigation on the
predictive role of KRAS mutation in bevacizumab-based
treatment. However, given the small sample and evidence of
great beneﬁt of bevacizumab independently of KRAS status, [6]
the preliminary nature of these results add a few more to what
was previously known and any conclusions about the present
analysis should be drawn very carefully.
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Association of telomerase
expression with recurrence of
sacral chordoma
Originated from the remnants of the notochord in the process
of fetal development, chordoma is a rare, slow growing and
locally invasive low-grade malignant tumor with an annual
incidence rate of 1/8 000 000 [1]. There are no standard
prognostic markers in this disease. This retrospective study
assessed telomerase in 20 patients of sacral chordoma (10
males and 10 females, aged 18–77 years). The samples of
tumor tissues were obtained intraoperatively from all the
patients, and samples of normal tissues 3 cm adjacent to the
tumors were from seven patients. Follow-ups were scheduled
every 3 to 6 months. Recurrence was evaluated from clinical
examinations and imaging. Surgical resection samples were
ﬁxed in formalin and embedded in parafﬁn block before sliced
into 4 μm in thickness for telomerase staining. Samples of
colorectal cancer were used as the positive control and
phosphate-buffered saline (PBS) was as the negative control.
The scale of percentage of the positive cell number was deﬁned
as 0, 0%; 1, 1–25%; 2, 26–50% and 3, >50%. The scale of the
color intensity was 0, none; 1, light brown; 2, brown and 3,
dark brown. The overall score was summarized from both
scales as 0, negative; 1–4, weakly positive and 5–6, strongly
positive.
Among the 20 patients, eleven of them had relapse.
Recurrence rates of 1, 3, 5 and 10 years were 5, 25, 55 and
90%, respectively. Telomerase expression was positive in all 20
cases (11 strongly positive and 9 weakly positive) (Fig. 1). The
peritumoral normal tissues had telomerase expression negative.
Positive expression of telomerase with chordoma recurrence
was signiﬁcantly higher than those without recurrence
(P = 0.003). Telomerase expression in relapse was signiﬁcantly
different from that without recurrence (P < 0.001).
To our knowledge, 20 patients are the largest clinical series
in sacral chordoma. Recurrence after surgical resection is a
common occurrence. Our study demonstrated the association
of telomerase expression with recurrence, suggesting that the
telomerase expression could be another predictor of recurrence
and survival.
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Figure 1. A typical telomerase expression of strongly positive chordoma
(streptavidin biotin peroxidase complex × 100).
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